野村发表研究报告指,中国生物制药(01177.HK) 去年收入按年增10%至318亿人民币,符合管理层双位数增长指引及该行预期,惟低于市场预测的331亿元人民币;纯利按年下跌33%至23亿元人民币,远低于市场预期的49亿元人民币。管理层表示non-HKFRS调整后利润为45亿人民币,按年增长31%。主要的非经常性项目导致差异的原因,是约21亿人民币的资产公允价值变动/减值。该行估计这可能与其对科兴...
Source Link野村发表研究报告指,中国生物制药(01177.HK) 去年收入按年增10%至318亿人民币,符合管理层双位数增长指引及该行预期,惟低于市场预测的331亿元人民币;纯利按年下跌33%至23亿元人民币,远低于市场预期的49亿元人民币。管理层表示non-HKFRS调整后利润为45亿人民币,按年增长31%。主要的非经常性项目导致差异的原因,是约21亿人民币的资产公允价值变动/减值。该行估计这可能与其对科兴...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.